Effects of androgens on bioactivity and immunoreactivity of pituitary FSH in GnRH antagonist-treated male rats.
The effects of androgens on the bioactivity and molecular composition of pituitary FSH were examined in intact and GnRH antagonist-suppressed male rats. Eight groups of adult Sprague-Dawley rats were subjected to the following treatments: antagonist (75 micrograms/day by osmotic minipumps; sc), testosterone-filled Silastic implants (3 X 5 cm, sc), dihydrotestosterone-filled Silastic implants (3 X 5 cm, sc), E2 benzoate (15 micrograms/day, sc), and combined administration of antagonist with either steroid for 3 weeks. At the end of the treatment period, pituitaries were dissected out and homogenised. FSH content was determined in the pituitary extracts by an in vitro bioassay and a radioimmunoassay. Individual pituitary extracts from rats treated with vehicle, testosterone and testosterone + antagonist were subjected to isoelectric-focusing on sucrose density gradients performed in the pH range from 3.5 to 7.0. Individual isoelectric-focusing fractions (100-120) were analysed for bioactive and immunoreactive FSH. Treatment with antagonist, E2 or antagonist + E2 caused a significant decrease in pituitary FSH, whereas testosterone and dihydrotestosterone alone or in combination with antagonist prevented the decrease in pituitary FSH. The effects of all treatments on both bioactive and immunoreactive FSH were similar. Testosterone treatment not only maintained FSH synthesis but also altered the molecular composition of pituitary FSH. Following treatment with testosterone there was a shift of maximal FSH bioactivity to the more acidic pH range. On the other hand, less bioactivity was recovered than corresponding immunoreactivity in the higher pH region, resulting in significantly reduced ratios of bioactivity to immunoreactivity of FSH.(ABSTRACT TRUNCATED AT 250 WORDS)
Sharma
O P
OP
Max Planck Clinical Research Unit for Reproductive Medicine, Münster, FRG.
Khan
S A
SA
Weinbauer
G F
GF
Arslan
M
M
Nieschlag
E
E
D000728:Androgens / Q000494:pharmacology*; D000818:Animals; D001682:Biological Availability; D013196:Dihydrotestosterone / Q000494:pharmacology; D005640:Follicle Stimulating Hormone / Q000032:analysis* / Q000096:biosynthesis; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors* / Q000502:physiology; D007525:Isoelectric Focusing; D008297:Male; D010902:Pituitary Gland / Q000032:analysis / Q000187:drug effects* / Q000378:metabolism; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D013739:Testosterone / Q000494:pharmacology
D000728:Androgens; D013196:Dihydrotestosterone; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D005640:Follicle Stimulating Hormone